Spinout News
Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise engineered Treg cell therapies for autoimmune diseases
9 June 2023
Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise autologous, engineered Treg cell therapies for two autoimmune disease indications.
Under the terms of the agreement, Quell’s proprietary toolbox of Treg cell engineering modules, including manipulation of Forkhead Box P3 (Foxp3), a technology developed by UCL Professors Han Stauss and Emma Morris, will be leveraged to develop autologous multi-modular Treg cell therapy candidates for Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD).
Quell was founded by life sciences VC company Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases. It unites academics from UCL, Kings College London and Hannover Medical School including, Professors Emma Morris and Hans Stauss from UCL, Professor Giovanna Lombardi, Dr Marc Martinez-Llordella and Professor Alberto Sánchez-Fueyo from King’s and Dr Elmar Jaeckel from Hannover.
Further information: